The Cigna Group (CI)

NYSE · Bloomfield, Connecticut, USA · Founded 1982 · CEO Brian Evanko

Valuation summary

$707.72 fair value versus $273.04 in the market, a difference of +159.2%. Rated Strong Buy.

Fair value per share$707.72
Current share price$273.04
Upside / downside+159.2%
Bear case$191.79
Bull case$1,557.16
Discount rate (WACC)8.9%
Terminal growth2.60%
Market capitalisation$72B
EV / Sales0.3x

About The Cigna Group

Formed in 1982 by the merger of Connecticut General and INA, with roots back to 1792. Brian Evanko succeeded David Cordani, chief executive since 2009, as CEO in July 2026, with Cordani becoming executive chair. The Cigna Group has two very different businesses: Evernorth, which contains Express Scripts, one of the three pharmacy benefit managers that negotiate drug prices for most Americans, and Cigna Healthcare, a commercial health insurer. Evernorth generates most of the profit and is where the political risk sits.

Investment case

  • Express Scripts is one of three pharmacy benefit managers controlling the vast majority of US prescription volume.
  • Exited Medicare Advantage, avoiding the utilisation problems that have hurt peers.
  • Specialty pharmacy is a large and structurally growing profit pool.

Key risks

  • Pharmacy benefit managers face intense bipartisan political scrutiny over drug pricing and rebate practices.
  • PBM reform passed in February 2026 delinks PBM pay from drug prices in Medicare Part D and requires full rebate pass-through for commercial plans, mostly from 2028 or 2029.
  • Commercial insurance is exposed to employment levels and medical cost trends.

Recent developments

Revenue by segment

Evernorth Health Services78%
Cigna Healthcare22%

Five-year forecast

RevenueFree cash flow
Year 1$307.4B$8.6B
Year 2$328.3B$9.7B
Year 3$350.7B$11.0B
Year 4$374.5B$12.5B
Year 5$400.0B$14.0B

What the street says

Cheap relative to peers, with the discount reflecting political risk to the PBM model rather than operational problems. At its September 2026 investor day the new management team reaffirmed 2026 adjusted EPS of at least $30.45 and set a 10-14% annual EPS growth target through 2030, but the shares fell about 3% because the outlook was not raised.

Comparable companies: CVS · ELV · COR · MDLN · HCA · CAH · IQV · GEHC

Open the interactive model, price chart and sensitivity grid →